Abstract. The efficacy of fluconazole was evaluated in 35 travelers with parasitologically proven imported Old World cutaneous leishmaniasis (CL). Leishmania major (mainly MON-25) was identified in 15 patients and strongly suspected given the transmission area in 12 of these patients. Daily oral fluconazole (200 mg/day for adults and 2.5 mg/kg/day for children) was prescribed for six weeks. Outcome definition was based on re-epithelialization rate at day 50. Of the 27 L. major-infected patients, 12 (44.4%) were cured. This cure rate is similar to the placebo cure rate from trials in L. major CL in which, as in the present report, the definition of outcome relied exclusively on re-epithelialization. These data question the assumption that or...
Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) often requires systemic therapy. Lip...
The treatment of Leishmaniasis caused by Leishmania (Viannia) guyanensis is based on a weak strength...
Leishmaniasis is endemic in 88 countries on five continents. There are 1–1.5 million cases of cutane...
The efficacy of fluconazole was evaluated in 35 travelers with parasitologically proven imported Old...
International audienceThe efficacy of fluconazole was evaluated in 35 travelers with parasitological...
International audienceBACKGROUND: Cutaneous leishmaniasis (CL) is a disfiguring but not life-threate...
We report for the first time the successful use of flucona-zole to treat cutaneous leishmaniasis due...
Background: Cutaneous leishmaniasis has an incidence of 0.7–1.2 million cases per year and represent...
Treatment of cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML) in travelers is still contr...
Guidelines recommend wound care and/or local therapy as first-line treatment for cutaneous leishmani...
International audienceOBJECTIVES: Cutaneous leishmaniasis (CL) in Asia, Northern, and Sub-Saharan Af...
International audienceBACKGROUND:Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) oft...
Treatment outcome was determined among a cohort of travellers who returned to the UK between Februar...
Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) often requires systemic therapy. Lip...
The treatment of Leishmaniasis caused by Leishmania (Viannia) guyanensis is based on a weak strength...
Leishmaniasis is endemic in 88 countries on five continents. There are 1–1.5 million cases of cutane...
The efficacy of fluconazole was evaluated in 35 travelers with parasitologically proven imported Old...
International audienceThe efficacy of fluconazole was evaluated in 35 travelers with parasitological...
International audienceBACKGROUND: Cutaneous leishmaniasis (CL) is a disfiguring but not life-threate...
We report for the first time the successful use of flucona-zole to treat cutaneous leishmaniasis due...
Background: Cutaneous leishmaniasis has an incidence of 0.7–1.2 million cases per year and represent...
Treatment of cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML) in travelers is still contr...
Guidelines recommend wound care and/or local therapy as first-line treatment for cutaneous leishmani...
International audienceOBJECTIVES: Cutaneous leishmaniasis (CL) in Asia, Northern, and Sub-Saharan Af...
International audienceBACKGROUND:Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) oft...
Treatment outcome was determined among a cohort of travellers who returned to the UK between Februar...
Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) often requires systemic therapy. Lip...
The treatment of Leishmaniasis caused by Leishmania (Viannia) guyanensis is based on a weak strength...
Leishmaniasis is endemic in 88 countries on five continents. There are 1–1.5 million cases of cutane...